Patents Represented by Attorney Isis Patent Department
-
Patent number: 7202264Abstract: Universal linkers, their facile processes of manufacture and methods of using the same are provided.Type: GrantFiled: November 15, 2004Date of Patent: April 10, 2007Assignee: Isis Pharmaceuticals, Inc.Inventors: Vasulinga Ravikumar, Muthiah Manoharan, Andrei P. Guzaev, Zhiwei Wang, Raju Krishna Kumar
-
Patent number: 7199107Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.Type: GrantFiled: November 17, 2003Date of Patent: April 3, 2007Assignee: ISIS Pharmaceuticals, Inc.Inventors: Kenneth W. Dobie, Erich Koller
-
Patent number: 7173123Abstract: Methods for detecting chloral hydrate in dichloroacetic acid are described.Type: GrantFiled: October 6, 2003Date of Patent: February 6, 2007Assignee: Isis Pharmaceuticals, Inc.Inventors: Patrick Wheeler, Daniel C. Capaldi
-
Patent number: 7169916Abstract: A process of manufacturing oligonucleotides includes a 5?-deblocking step in which the 5-blocking group is removed with dichloroacetic acid that is essentially free of chloral. The process is useful for making oligonucleotides that are substantially free of chloral adducts.Type: GrantFiled: March 31, 2003Date of Patent: January 30, 2007Assignee: Isis Pharmaceuticals, Inc.Inventors: Achim Krotz, Daniel Capaldi, Hans Gaus, Brett Turney
-
Patent number: 7138517Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specifically hybridizable with a selected sequence of RNA or DNA wherein at least one of the 2?-deoxyfuranosyl moieties of the nucleoside unit is modified. Treatment of diseases caused by various viruses and other causative agents is provided.Type: GrantFiled: November 28, 2001Date of Patent: November 21, 2006Assignee: Isis Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Andrew Mamoru Kawasaki
-
Patent number: 7125975Abstract: Linked nucleosides having at least one functionalized nucleoside that bears a substituent such as a steroid molecule, a reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme, a peptide, a protein, a water soluble vitamin, a lipid soluble vitamin, an RNA cleaving complex, a metal chelator, a porphyrin, an alkylator, a pyrene, a hybrid photonuclease/intercalator, or an aryl azide photo-crosslinking agent exhibit increased cellular uptake and other properties. The substituent can be attached at the 2?-position of the functionalized nucleoside via a linking group. If at least a portion of the remaining liked nucleosides are 2?-deoxy-2?-fluoro, 2?-O-methoxy, 2?-O-ethoxy, 2?-O-propoxy, 2?-O-aminoalkoxy or 2?-O-allyloxy nucleosides, the substituent can be attached via a linking group at any of the 3? or the 5? positions of the nucleoside or on the heterocyclic base of the nucleoside or on the inter-nucleotide linkage linking the nucleoside to an adjacent nucleoside.Type: GrantFiled: January 9, 2004Date of Patent: October 24, 2006Assignee: Isis Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Phillip Dan Cook, Clarence Frank Bennett
-
Patent number: 7122649Abstract: Linked nucleosides having at least one functionalized nucleoside that bears a substituent such as a steroid molecule, a reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme, a peptide, a protein, a water soluble vitamin, a lipid soluble vitamin, an RNA cleaving complex, a metal chelator, a porphyrin, an alkylator, a pyrene, a hybrid photonuclease/intercalator, or an aryl azide photo-crosslinking agent exhibit increased cellular uptake and other properties. The substituent can be attached at the 2?-position of the functionalized nucleoside via a linking group. If at least a portion of the remaining liked nucleosides are 2?-deoxy-2?-fluoro, 2?-O-methoxy, 2?-O-ethoxy, 2?-O-propoxy, 2?-O-aminoalkoxy or 2?-O-allyloxy nucleosides, the substituent can be attached via a linking group at any of the 3? or the 5? positions of the nucleoside or on the heterocyclic base of the nucleoside or on the inter-nucleotide linkage linking the nucleoside to an adjacent nucleoside.Type: GrantFiled: January 9, 2004Date of Patent: October 17, 2006Assignee: Isis Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Phillip Dan Cook, Clarence Frank Bennett
-
Patent number: 7119184Abstract: Modified oligonucleotides containing both A-form conformation geometry and B-from conformation geometry nucleotides are disclosed. The B-form geometry allows the oligonucleotide to serve as substrates for RNase H when bound to a target nucleic acid strand. The A-form geometry imparts properties to the oligonucleotide that modulate binding affinity and nuclease resistance. By utilizing C2? endo sugars or O4? endo sugars, the B-form characteristics are imparted to a portion of the oligonucleotide. The A-form characteristics are imparted via use of either 2?-O-modified nucleotides that have 3? endo geometries or use of end caps having particular nuclease stability or by use of both of these in conjunction with each other.Type: GrantFiled: October 4, 2001Date of Patent: October 10, 2006Assignee: Isis Pharmaceuticals, Inc.Inventors: Muthiah Manoharan, Venkatraman Mohan, Phillip Dan Cook, Andrew M. Kawasaki
-
Patent number: 7108974Abstract: Method for detecting and identifying unknown bioagents, including bacteria, viruses and the like, by a combination of nucleic acid amplification and molecular weight determination using primers which hybridize to conserved sequence regions of nucleic acids derived from a bioagent and which bracket variable sequence regions that uniquely identify the bioagent. The result is a “base composition signature” (BCS) which is then matched against a database of base composition signatures, by which the bioagent is identified.Type: GrantFiled: May 24, 2002Date of Patent: September 19, 2006Assignee: Isis Pharmaceuticals, Inc.Inventors: David J. Ecker, Richard Griffey, Rangarajan Sampath, Steven Hofstadler, John McNeil
-
Patent number: 7101993Abstract: Compounds are provided containing purine nucleotides that bear moieties X at the 2? position thereof wherein X is R1—(R2)n; R1 is C3-C20 alkyl, C4-C20 alkenyl or C2-C20 alkynyl; R2 is halogen, hydroxyl, thiol, keto, carboxyl, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, O-alkyl, S-alkyl, NH-alkyl, N-dialkyl, O-aryl, S-aryl, NH-aryl, O-aralkyl, S-aralkyl, NH-aralkyl, amino, N-phthalimido, imidazole, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, aryl, heterocycle, carbocycle, intercalator, reporter molecule, conjugate, polyamine, polyamide, polyalkylene glycol, polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, or a group that enhances the pharmacokinetic properties of oligonucleotides; and n is an integer from 0 to about 6. Such compounds are useful for modulating the synthesis of proteins.Type: GrantFiled: October 27, 1992Date of Patent: September 5, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Daniel Peter Claude McGee, Charles John Guinosso
-
Patent number: 7067497Abstract: Modified oligonucleotides having a GGG motif sequence and a sufficient number of flanking nucleotides to modulate the telomere length of a chromosome are provided. Methods of modulating telomere length of a mammalian chromosome in vitro and in vivo are also provided, as are methods for inhibiting the division of a malignant mammalian cell and for modulating the effects of cellular aging.Type: GrantFiled: January 2, 2002Date of Patent: June 27, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Ronnie C. Hanecak, Kevin P. Anderson, C. Frank Bennett, Ming-Yi Chiang, Vickie L. Brown-Driver, David J. Ecker, Timothy A. Vickers, Jacqueline R. Wyatt
-
Patent number: 7057062Abstract: A scalable process for purification of phosphorodiamidite includes steps of solubilizing a crude phosphorodiamidite in an apolar organic solvent, contacting the non-polar organic solvent with a polar phase comprising a polar organic solvent to remove impurities from the solubilized phosphorodiamidite, and removing the non-polar organic solvent from the phosphorodiamidite.Type: GrantFiled: April 11, 2002Date of Patent: June 6, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Quanlai Song, Bruce Ross
-
Patent number: 7041816Abstract: Synthetic processes are provided wherein oligomeric compounds are prepared having phosphodiester, phosphorothioate, phosphorodithioate, or other covalent linkages. The oligomers have substantially reduced exocyclic adducts deriving from acrylonitrile or related contaminants.Type: GrantFiled: January 20, 2004Date of Patent: May 9, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Vasulinga T. Ravikumar, Muthiah Manoharan, Daniel C. Capaldi, Achim Krotz, Douglas L. Cole, Andrei Guzaev
-
Patent number: 7037646Abstract: Nucleosides and oligonucleosides functionalized to include alkylamino functionality, and derivatives thereof. In certain embodiments, the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins attached to the nucleosides through the alkylamino group.Type: GrantFiled: September 2, 1994Date of Patent: May 2, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Muthiah Manoharan, Charles J. Guinosso
-
Patent number: 7038037Abstract: A sequential support-bound synthesis method is disclosed for preparing a conjugated oligomeric compound, preferably a PNA-peptide conjugate or an oligonucleotide-peptide conjugate, using a bridging molecule having at least two N-protecting amino groups. A conjugated oligomeric compound for therapeutic or prophylactic delivery is also disclosed.Type: GrantFiled: June 20, 2002Date of Patent: May 2, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Martin A. Maier, Andrei P. Guzaev, Muthiah Manoharan
-
Patent number: 7033830Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MyD88. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MyD88. Methods of using these compounds for modulation of MyD88 expression and for treatment of diseases associated with expression of MyD88 are provided.Type: GrantFiled: September 26, 2003Date of Patent: April 25, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: James Karras, Kenneth Dobie
-
Patent number: 7030230Abstract: A process of purifying phosphoramidite precursors useful in inter alia synthesis of oligonucleotides comprises dissolving a crude phosphoramidite in a polar phase, adding a basic compound to the polar phase, adding a portion of water to the polar phase, contacting the polar phase with a first apolar phase to extract impurity into the apolar phase, separating the first apolar phase from the polar phase, adding a second aliquot of water to the polar phase, and contacting the polar phase with a second apolar phase, whereby the phosphoramidite partitions into the second apolar phase.Type: GrantFiled: October 25, 2002Date of Patent: April 18, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Bruce Ross, Quanlai Song
-
Patent number: 7015315Abstract: Oligonucleotides and other macromolecules are provided which have increased nuclease resistance, substituent groups for increasing binding affinity to complementary strand, and subsequences of 2?-deoxy-erythro-pentofuranosyl nucleotides that activate RNase H. Such oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics.Type: GrantFiled: June 6, 1995Date of Patent: March 21, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Phillip Dan Cook, Brett P. Monia
-
Patent number: RE39324Abstract: Compounds having structure (1) wherein R1 is —H a protecting group, a linker or a binding partner; and R2 and R34 are as defined in the specification. The invention also provides intermediates and methods make the structure (1) compounds, as well as methods to use the compounds as labels in diagnostic assays and to enhance binding to complementary bases.Type: GrantFiled: February 21, 2002Date of Patent: October 3, 2006Assignee: ISIS Pharmaceuticals, Inc.Inventors: Kuei-Ying Lin, Mark D. Matteucci
-
Patent number: RE39464Abstract: Novel chiral compounds that mimic and/or modulate the activity of wild-type nucleic acids are disclosed. In general, the compounds are phosphorothioate oligonucleotides wherein the 5?, and the 3?-terminal internucleoside linkages are chirally Sp and internal internucleoside linkages are chirally Rp.Type: GrantFiled: August 24, 2004Date of Patent: January 9, 2007Assignee: ISIS Pharmaceuticals Inc.Inventors: Phillip Dan Cook, Muthiah Manoharan